Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

JBR Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$23,803,690

1,134 payments

Through program year 2025, JBR Clinical Research is reported as receiving $23,803,690 in research payments, across 1,134 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,197,987 10
2024 Research $2,669,766 87
2023 Research $10,571,352 467
2022 Research $5,229,311 497
2021 Research $3,454,198 23
2020 Research $499,619 33
2019 Research $181,456 17

Breakdown

Who paid Research payments · program years 2019–2025
  1. Vertex Pharmaceuticals Incorporated $16,213,852 19 payments
  2. Moderna TX, Inc. $2,927,824 1,019 payments
  3. Baudax Bio Inc. $1,568,756 13 payments
  4. ACADIA Pharmaceuticals Inc $1,288,381 14 payments
  5. Mylan Pharmaceuticals Inc. $793,313 7 payments
  6. Mylan Inc. $610,320 9 payments
  7. Pfizer Inc. $141,089 21 payments
  8. DPT Laboratories, Ltd. $103,477 6 payments
  9. GlaxoSmithKline, LLC. $82,771 16 payments
  10. Perrigo Company plc $57,169 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty $6,371,081 2 payments
  2. A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy $4,304,543 3 payments
  3. A Phase 2 Randomized Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty $1,982,097 1 payment
  4. A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy $1,279,714 2 payments
  5. A Phase 2 randomized double blind placebo controlled study evaluating the efficacy and safety of VX-548 for acute pain after an abdominoplasty $989,392 1 payment
  6. Acp-044-004 $845,961 9 payments
  7. A Phase 2, Randomized, Double-blind, Placebo controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy $810,695 2 payments
  8. Mecc-Tbz-2001 $793,313 7 payments
  9. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $660,156 6 payments
  10. A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age $584,749 33 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $1,562,512 12 payments
  2. Other $103,477 6 payments
  3. Non-patient care $6,244 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record